ES2040697T3 - Concentrado de nifedipina estabilizado frente a la influencia de la luz, y procedimiento para su preparacion. - Google Patents

Concentrado de nifedipina estabilizado frente a la influencia de la luz, y procedimiento para su preparacion.

Info

Publication number
ES2040697T3
ES2040697T3 ES198686117660T ES86117660T ES2040697T3 ES 2040697 T3 ES2040697 T3 ES 2040697T3 ES 198686117660 T ES198686117660 T ES 198686117660T ES 86117660 T ES86117660 T ES 86117660T ES 2040697 T3 ES2040697 T3 ES 2040697T3
Authority
ES
Spain
Prior art keywords
nifedipine
influence
procedure
preparation
light
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES198686117660T
Other languages
English (en)
Inventor
Kurt H. Prof. Dr. Bauer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of ES2040697T3 publication Critical patent/ES2040697T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

SE DESCRIUBE UN CONCENTRADO DE NIFEDIPINA ESTABILIZADO FRENTE A LA INFLUENCIA DE LA LUZ QUE SE CARACTERIZA PORQUE CONTIENE NIFEDIPINA, POLIETILENGLUCOL, 0,5 A 20% DE PESO DE VITAMINA B2, REFERIDO A LA NIFEDIPINA, AL MENOS EN TENSIDO Y DADO EL CASO LOS HABITUALES SOPORTES. SE DESCRIBE ADEMAS UN PROCEDIMIENTO PARA LA FABRICACION DEL CONCENTRADO DE NIFEDIPINA ASI COMO UN MEDICAMENTO QUE LO CONTIENE Y LA UTILIZACION PARA LA FABRICACION DE MEDICAMENTOS.
ES198686117660T 1986-12-18 1986-12-18 Concentrado de nifedipina estabilizado frente a la influencia de la luz, y procedimiento para su preparacion. Expired - Lifetime ES2040697T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP86117660A EP0272336B1 (de) 1986-12-18 1986-12-18 Gegenüber Lichteinfluss stabilisiertes Nifedipin-Konzentrat und Verfahren zu seiner Herstellung

Publications (1)

Publication Number Publication Date
ES2040697T3 true ES2040697T3 (es) 1993-11-01

Family

ID=8195654

Family Applications (1)

Application Number Title Priority Date Filing Date
ES198686117660T Expired - Lifetime ES2040697T3 (es) 1986-12-18 1986-12-18 Concentrado de nifedipina estabilizado frente a la influencia de la luz, y procedimiento para su preparacion.

Country Status (7)

Country Link
US (1) US4904699A (es)
EP (1) EP0272336B1 (es)
JP (1) JPS63165318A (es)
AT (1) ATE68704T1 (es)
DE (1) DE3682208D1 (es)
ES (1) ES2040697T3 (es)
GR (1) GR3003631T3 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3738236A1 (de) * 1987-11-11 1989-05-24 Euro Celtique Sa Beisskapsel
HUT59592A (en) * 1990-07-20 1992-06-29 Egyt Gyogyszervegyeszeti Gyar Process for the preparation of solid medical products
US5145859A (en) * 1991-03-20 1992-09-08 Case Western Reserve University Methods of treating interstitial cystitis and urethral syndrome
US5229130A (en) * 1991-12-20 1993-07-20 Cygnus Therapeutics Systems Vegetable oil-based skin permeation enhancer compositions, and associated methods and systems
BE1006990A5 (nl) * 1993-04-22 1995-02-07 Univ Gent Werkwijze en samenstelling om een aktief bestanddeel in een vaste toedieningsvorm te brengen.
US6726930B1 (en) * 1993-09-09 2004-04-27 Penwest Pharmaceuticals Co. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5773025A (en) * 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
US5662933A (en) * 1993-09-09 1997-09-02 Edward Mendell Co., Inc. Controlled release formulation (albuterol)
US5455046A (en) * 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5994348A (en) 1995-06-07 1999-11-30 Sanofi Pharmaceutical compositions containing irbesartan
AU695734B2 (en) 1996-07-08 1998-08-20 Penwest Pharmaceuticals Co. Sustained release matrix for high-dose insoluble drugs
US6056977A (en) 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation
US6168806B1 (en) 1999-03-05 2001-01-02 Fang-Yu Lee Orally administrable nifedipine pellet and process for the preparation thereof
DE19913692A1 (de) * 1999-03-25 2000-09-28 Basf Ag Mechanisch stabile pharmazeutische Darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive Substanzen
WO2001022940A1 (en) * 1999-09-30 2001-04-05 Edward Mendell Co., Inc. Sustained release matrix systems for highly soluble drugs
US7364752B1 (en) 1999-11-12 2008-04-29 Abbott Laboratories Solid dispersion pharamaceutical formulations
JP5767429B2 (ja) * 1999-11-12 2015-08-19 アッヴィ・インコーポレイテッド 固体分散剤中の結晶化阻害剤
DE10026698A1 (de) * 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
CA2519779A1 (en) * 2003-03-26 2004-10-14 Teva Pharmaceutical Industries Ltd. A process for preparing a pharmaceutical active ingredient with high specific surface area
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
WO2008067164A2 (en) * 2006-11-15 2008-06-05 Abbott Laboratories Solid pharmaceutical dosage formulations
GB0703514D0 (en) * 2007-02-23 2007-04-04 Univ Ulster Use of riboflavin
JP6215238B2 (ja) * 2012-02-16 2017-10-18 テバ ファーマシューティカル インダストリーズ リミティド N−エチル−n−フェニル−1,2−ジヒドロ−4,5−ジ−ヒドロキシ−1−メチル−2−オキソ−3−キノリンカルボキサミド、その製剤、および使用
CA2968861C (en) 2017-05-30 2022-10-11 University Of Saskatchewan Topical nifedipine formulations and uses thereof
JP7443663B2 (ja) * 2018-11-07 2024-03-06 ディーエスエム アイピー アセッツ ビー.ブイ. 改善された流動性を示す、リボフラビンを含有する薬剤

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU432703A3 (es) * 1971-08-24 1974-06-15 Фридрих Боссерт, Вульф Фатер, Курт Бауер
GB1579818A (en) * 1977-06-07 1980-11-26 Yamanouchi Pharma Co Ltd Nifedipine-containing solid preparation composition
GB2111978B (en) * 1981-10-19 1985-05-01 Maruko Pharmaceutical Co 1 4-dihydropyridine compounds
DE3339236A1 (de) * 1983-10-28 1985-05-09 Bayer Ag Arzneimittelzubereitung
DE3438830A1 (de) * 1984-10-23 1986-04-30 Rentschler Arzneimittel Nifedipin enthaltende darreichungsform und verfahren zu ihrer herstellung
DE3532129A1 (de) * 1985-09-10 1987-03-12 Bayer Ag Ss-carotin enthaltende gelatine

Also Published As

Publication number Publication date
EP0272336A1 (de) 1988-06-29
GR3003631T3 (es) 1993-03-16
JPS63165318A (ja) 1988-07-08
DE3682208D1 (de) 1991-11-28
ATE68704T1 (de) 1991-11-15
US4904699A (en) 1990-02-27
EP0272336B1 (de) 1991-10-23

Similar Documents

Publication Publication Date Title
ES2040697T3 (es) Concentrado de nifedipina estabilizado frente a la influencia de la luz, y procedimiento para su preparacion.
ES553266A0 (es) Procedimiento para la preparacion de dipeptidos de n,n'-dialquilguanidino
ATE53301T1 (de) Systeme zur verbesserung der durchdringungsfaehigkeit und deren zubereitung.
IT8523299A0 (it) Derivati. processo per la preparazione di (2,2)-paraciclofano e suoi
ES515301A0 (es) "procedimiento para la preparacion de derivados de urea".
MX162864B (es) Procedimiento para la preparacion de 2,2,6,6-tetraalquil-4-piperidilaminas
ES556109A0 (es) Un metodo para la estabilizacion de formulaciones blanqueantes acuosas
DK554084A (da) 26,26,26,27,27,27-hexafluor-1alfa,25-dihydroxycholesterol
MX7769A (es) Procedimiento para la preparacion de derivados de pirimidina.
IT8620939A0 (it) Processo per la preparazione di (2,2)-paraciclofano e suoi derivati.
ES556369A0 (es) Procedimiento para la obtencion de acidos 4-quinolon-3-carboxilicos 1,8- puenteados.
MX162554A (es) Procedimiento mejorado para la preparacion de 2,4,6-tris-(aminofenilamino)triazinas
ATE104554T1 (de) Topische praeparate.
MX17041A (es) Procedimiento para la preparacion de benzopirano pirazoles.
ES555497A0 (es) Un procedimiento para la preparacion de (e)-3-metil-5(2,2,3-trimetilciclopent -3-evo-1-ilo) pent-4-eno-2-ol
PT84130B (pt) Processo para a preparacao de novos derivados de 3-alcoxiflavonas e das respectivas composicoes farmaceuticas
MX15050A (es) Procedimiento para la preparacion de derivados de 1-arilsulfinil-2-pirrolidinona.
ES549378A0 (es) Procedimiento para la preparacion de derivados de 1,3,4-tia-diazol
PT82548B (pt) Processo para a preparacao de acidos 4(z)-6-({2,4,5-cis}-4-o-hidroxifenil-2-trifluormetil-1,3-dioxan-5-il)-hexenoico e de composicoes farmaceuticas que os contem
ES513723A0 (es) Un procedimiento para la preparacion de derivados de cistina".
RO88858A (ro) Compozitie erbicida
ES549906A0 (es) Procedimiento para la preparacion de derivados de 1,4-dihi- dropiridina
ITMI930520A1 (it) Procedimento per la preparazione di disperdenti solfonati.
MX6790A (es) Procedimiento para la preparacion de nuevos derivados de aralquilimidazol, productos obtenidos y composicion farmaceutica que los incluye.
ATE87902T1 (de) Derivate von 2,2-dimethylcyclopropancarbonsaeure.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 272336

Country of ref document: ES